Lycia Therapeutics Inc. (LYCA)

NASDAQ Healthcare Biotechnology

Lycia Therapeutics Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in South San Francisco, CA, US. The stock last traded at $30.00, up 66.67% on the session, giving a market capitalisation of $1.56B. Its beta of 0.00 implies it has historically moved less than the broad market.

Lycia Therapeutics, Inc. operates as a clinical-stage biotechnology company. It engages in the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory, and allergic diseases. The company was founded in 2019 and is headquartered in South San Francisco, CA.